Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07645976
Home Environmental Risks and Caregiver AwarenessMarmara University Pendik Training and Research HospitalCompleted
NCT07644429
Biomechanical Characterisation of 3D Printed Comfort InsolesUniversity of PecsActive Not RecruitingNot Applicable
NCT07644429Active Not Recruiting
Not Applicable
Biomechanical Characterisation of 3D Printed Comfort InsolesUniversity of Pecs
NCT07646015
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic DisordersJSS Medical College HospitalCompleted
NCT07646015Completed
—
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, L...JSS Medical College Hospi...
NCT07644728
Sleep Quality and Biomarkers in Adolescent Girls With Anorexia NervosaUniversity Hospital of SplitNot Yet Recruiting
NCT07644728Not Yet Recruiting
—
Sleep Quality and Biomarkers in Adolescent Girls With Anorexia NervosaUniversity Hospital of Sp...
NCT07645846
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaFirst Affiliated Hospital, Sun Yat-Sen UniversityNot Yet RecruitingPhase 2
NCT07645846Not Yet Recruiting
Phase 2
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaFirst Affiliated Hospital...
NCT07645534
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.Valenta Pharm JSCRecruitingPhase 1
NCT07645534Recruiting
Phase 1
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta...Valenta Pharm JSC
NCT07645469
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaFred Hutchinson Cancer CenterNot Yet RecruitingPhase 1
NCT07645469Not Yet Recruiting
Phase 1
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Di...Fred Hutchinson Cancer Ce...
NCT07644143
Effect of A Theory-based Multicomponent eHealth Intervention ProgramTaipei Medical UniversityNot Yet RecruitingNot Applicable
NCT07644143Not Yet Recruiting
Not Applicable
Effect of A Theory-based Multicomponent eHealth Intervention ProgramTaipei Medical University
NCT07645118
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal CancerDr. Te VuongNot Yet RecruitingPhase 2
NCT07645118Not Yet Recruiting
Phase 2
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal CancerDr. Te Vuong
NCT07645157
Sertraline Combined With Multi-Strain Probiotics for Adolescent DepressionFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingPhase 2
NCT07645157Recruiting
Phase 2
Sertraline Combined With Multi-Strain Probiotics for Adolescent DepressionFirst Affiliated Hospital...
NCT07643831
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast CancerGenentech, Inc.Unknown
NCT07643831Unknown
—
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2-...Genentech, Inc.
NCT07643818
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron DeficiencyGovernment of JerseyNot Yet RecruitingPhase 2
NCT07643818Not Yet Recruiting
Phase 2
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in H...Government of Jersey
NCT07645209
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsChina-Japan Union Hospital, Jilin UniversityActive Not Recruiting
NCT07645209Active Not Recruiting
—
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Canc...China-Japan Union Hospita...
NCT07645287
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Gilead SciencesNot Yet RecruitingPhase 2
NCT07645287Not Yet Recruiting
Phase 2
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologica...Gilead Sciences
NCT07646249
VENtilation Modalities During Transport of PostoperatIve CRITically Ill Patients to the ICUAzienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di AlessandriaNot Yet Recruiting
NCT07646249Not Yet Recruiting
—
VENtilation Modalities During Transport of PostoperatIve CRITically Ill Patients...Azienda Ospedaliera SS. A...
NCT07644533
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced CancerAffiliated Hospital of Qinghai UniversityNot Yet RecruitingNot Applicable
NCT07644533Not Yet Recruiting
Not Applicable
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in...Affiliated Hospital of Qi...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646132
Focal Extracorporeal Shock Wave Therapy With Two Different Dosing Regimens for Chronic Low Back PainArmando Tonatiuh Avila GarciaNot Yet RecruitingNot Applicable
NCT07646132Not Yet Recruiting
Not Applicable
Focal Extracorporeal Shock Wave Therapy With Two Different Dosing Regimens for C...Armando Tonatiuh Avila Ga...
NCT07646002
Effectiveness of Balloon Blowing and Deep Breathing Exercise on Increasing Peripheral Oxygen Saturation in Patients With Chronic Obstructive Pulmonary DiseaseIndonesia UniversityCompletedNot Applicable
NCT07646002Completed
Not Applicable
Effectiveness of Balloon Blowing and Deep Breathing Exercise on Increasing Perip...Indonesia University
NCT07646353
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy AdultsGlaxoSmithKlineNot Yet RecruitingPhase 1
NCT07646353Not Yet Recruiting
Phase 1
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in H...GlaxoSmithKline
Result Breakdown
Not yet recruiting11 (55%)
Completed3 (15%)
Recruiting3 (15%)
Active, not recruiting2 (10%)
Unknown1 (5%)
Not Specified6 (30%)
Phase 26 (30%)
not_applicable5 (25%)
Phase 13 (15%)